| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Product revenues, net | 142,342 | 107,415 | 92,823 | 93,425 |
| Selling, general and administrative | - | - | - | 118,930 |
| Cost of product revenues (excluding amortization of intangible assets) | 29,365 | 28,075 | 21,278 | 21,170 |
| Research and development | 186,415 | 177,190 | 152,577 | 150,809 |
| Selling, general and administrative | 186,376 | 154,763 | 147,545 | - |
| Amortization of intangible assets | 1,538 | 1,263 | 1,263 | 1,263 |
| Change in fair value of deferred and contingent consideration liabilities | 104,653 | 59,000 | 18,300 | 14,682 |
| Total operating expenses | 508,347 | 420,291 | 340,963 | 306,854 |
| Operating loss | -366,005 | -312,876 | -248,140 | -213,429 |
| Investment income | 18,289 | 13,225 | 13,906 | 16,982 |
| Interest expense | 20,382 | 21,245 | 21,569 | 21,054 |
| Change in fair value of interest rate swap | 0 | 0 | - | -3,852 |
| Other (expense) income, net | -603 | 453 | 132 | 1,843 |
| Loss before income taxes | -368,701 | -320,443 | -255,671 | -219,510 |
| Provision for income taxes | 1,320 | 1,243 | 912 | 1,014 |
| Net loss | -370,021 | -321,686 | -256,583 | -220,524 |
| Basic net loss per share (in dollars per share) | -1.75 | -1.7 | -1.42 | -1.27 |
| Diluted net loss per share (in dollars per share) | -1.75 | -1.7 | -1.42 | -1.27 |
| Weighted average basic common shares outstanding (in shares) | 211,759,000 | 189,302,000 | 180,860,000 | 173,721,000 |
| Weighted average diluted common shares outstanding (in shares) | 211,759,000 | 189,302,000 | 180,860,000 | 173,721,000 |
INSMED Inc (INSM)
INSMED Inc (INSM)